Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
To demonstrate that the efficacy of secukinumab monotherapy (300 mg s.c.) at Week 52 is superior to adalimumab monotherapy (40 mg s.c.) based on the proportion of subjects achieving an American College of Rheumatology 20 (ACR20) response.
Inclusion criteria
- Psoriatic Arthritis